title: Long term result of intravitreal bevacizumab in a patient newly transformed to proliferative macular telangiectasia type 2.
abstract: The clinical and imaging findings and therapeutic outcomes of intravitreal bevacizumab injection in a patient with macular telangiectasia type 2 are described. The patient first presented with the non-proliferative stage of the disease for 4 months, then the disease transformed to the proliferative stage. In the proliferative period, the patient was treated with intravitreal bevacizumab injections as-clinically warranted. Over a follow up period lasting 26 months, the patient received 6 intravitreal bevacizumab injections, the visual acuity improved from 20/100 to 20/40, the central retinal thickness decreased from 318 microns to 198 microns. This case implies that the patients with non-proliferative macular telangiectasia type 2 should be followed carefully for proliferative transformation, and intravitreal bevacizumab treatment seems to be effective for proliferative macular telangiectasia type 2.
authors: Beyoğlu Eye Research and Training Hospital, Beyoğlu, Istanbul, Turkey.
authors: Abdullah
authors: A
authors: Ozkaya
authors: Zeynep
authors: Z
authors: Alkin
authors: Yalcin
authors: Y
authors: Karakucuk
authors: Ahmet Taylan
authors: AT
authors: Yazici
authors: Ahmet
authors: A
authors: Demirok
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000068258:Bevacizumab; D005260:Female; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D006801:Humans; D058449:Intravitreal Injections; D008875:Middle Aged; D015861:Retinal Neovascularization / Q000175:diagnosis / Q000188:drug therapy*; D058456:Retinal Telangiectasis / Q000145:classification / Q000175:diagnosis / Q000188:drug therapy*; D058471:Subretinal Fluid; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000502:physiology
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab
keywords: Intravitreal Bevacizumab; Macular Telangiectasia; Subretinal Neovascularization